Novo Nordisk’s diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Rybelsus is a glucagon-like peptide-1 (GLP-1) agonist available as a tablet. It is used to treat type 2 diabetes. Metformin ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

April 2 (Reuters) - (To receive the full newsletter in your inbox for free sign up here) Novo Nordisk’s (NOVOb.CO), opens new tab diabetes medicine Rybelsus, an oral form of the GLP-1 drug ...